IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) was downgraded by equities research analysts at Maxim Group from a “buy” rating to a “hold” rating in a research report issued on Friday, Marketbeat.com reports.
The analysts wrote, “Reported this morning, 4Q17 revenues were $1.08M, down from $1.19M in 3Q17. The company ended the period with $1.9M in cash, but as of February 2018, has just $0.6M in cash. Management expects this to last until June even when considering quarterly profit share payments from Par Pharmaceuticals (private) and Mallinckrodt (MNK – NR). As such, we expect the company will need to raise capital which will likely be dilutive, and along with sequentially lower revenue in 4Q, we downgrade the shares to Hold, from Buy, and remove the price target.””
IPCI has been the topic of several other research reports. Zacks Investment Research raised shares of IntelliPharmaCeutics Intl from a “sell” rating to a “hold” rating in a report on Wednesday, December 13th. HC Wainwright started coverage on shares of IntelliPharmaCeutics Intl in a research note on Friday, January 19th. They set a “buy” rating and a $2.50 price target on the stock. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. IntelliPharmaCeutics Intl presently has a consensus rating of “Hold” and an average target price of $2.53.
Institutional investors have recently added to or reduced their stakes in the stock. Advisor Group Inc. raised its stake in IntelliPharmaCeutics Intl by 57.7% during the second quarter. Advisor Group Inc. now owns 47,409 shares of the company’s stock valued at $100,000 after purchasing an additional 17,342 shares in the last quarter. Sabby Management LLC purchased a new stake in IntelliPharmaCeutics Intl during the fourth quarter valued at $867,000. Finally, Armistice Capital LLC purchased a new stake in IntelliPharmaCeutics Intl during the fourth quarter valued at $1,549,000. 3.28% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “IntelliPharmaCeutics Intl (IPCI) Lowered to “Hold” at Maxim Group” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2018/02/18/intellipharmaceutics-intl-ipci-lowered-to-hold-at-maxim-group.html.
About IntelliPharmaCeutics Intl
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.